A new test has been developed to make the vital distinction between aggressive and less harmful forms of prostate cancer, helping to avoid sometimes-damaging unnecessary treatment. Each year 46,000 men in the UK develop prostate cancer and many cancers...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mChJ0X
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Abstract Background We have previously published data from 2001 to 2006 showing that adolescent and young adult (AYA) oncology patients ...
-
Abstract Desmoplastic small round cell tumor (DSCRT) is a rare malignancy most often seen in the abdomen or pelvis of young men. Unfortuna...
-
Here is your sample essay on Advertising Advertising is an important element of our culture because it reflects and attempts to change our l...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nGQ2DC via IFTTT
-
CXCR4: A New Player in an Old Scene? ORL J Otorhinolaryngol Relat Spec. 2017 Feb 24;79(1-2):34-42 Authors: Knopf A, Fritsche MK, Li Y...
-
Objective To determine the association between neuroendocrine tumor (NET) biomarker levels and the extent of disease as assessed by 68 Ga DO...
-
Abstract Ankylosing spondylitis (AS) is characterized by excessive bone formation with syndesmophytes, leading to bony ankylosis. The cont...
-
by Mindaugas Paužuolis, Torsten Eich, Joachim Burman Background Natalizumab (NTZ) is a drug that has been widely used in the treatment of m...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου